Worldwide Clinical Trials
and Thomas Jefferson University’s School of Population Health, under the direction of David B. Nash, MD, MBA, announced that they have entered into an alliance to provide pharmaceutical and biotechnology clients with a broad range of outcomes research services including comparative effectiveness, burden of illness, and quality of life studies. The alliance couples Worldwide Clinical Trials’ unparalleled operational and medical expertise with JSPH’s academic leadership in the field of economic evaluation of health care interventions.
“We are very pleased to be working with Dr. Nash and his team and to offer our clients the highest standards in industry-sponsored clinical research,” said Mike Murphy, MD, PhD, Chief Medical and Scientific Officer of Worldwide Clinical Trials. “To my knowledge, this alliance is the first of its kind, representing a visionary approach that integrates methodological rigor across a suite of services and joins highly complementary teams to preemptively address the needs of all healthcare constituents.”
“This is the type of research that clinicians will need in order to improve the quality of clinical care,” said Dr. Nash. “The School of Population Health’s alliance with Worldwide Clinical Trials is critical and could not come at a better time. The evidence is overwhelming that autonomous decision-making without a solid evidentiary basis leads to waste and a propensity for medical error.”
Historically, clinical development plans have focused on regulatory requirements for demonstrating efficacy, tolerability, and safety. Less emphasis has been placed during the pre-registration period on designing clinical programs to provide a data platform that addresses healthcare outcomes, quality-of-life initiatives, direct medical costs, and indirect costs (lost productivity). In the current healthcare environment, it is imperative to incorporate the perspective of multiple stakeholders into the clinical development process from its inception. Program design viewed through the prism of an expanded healthcare audience will facilitate informed health technologies assessments, formulary placement decisions, and algorithms for reimbursement—addressing issues of cost, quality, and patient access within a clinical, business, and regulatory environment.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.